Literature DB >> 22203545

Pharmacogenomics and clopidogrel: irrational exuberance?

Steven E Nissen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22203545     DOI： 10.1001/jama.2011.1865

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  16 in total

1.  Publishing genomic studies: walking the fine line.

Authors:  Arthur M Feldman
Journal:  Clin Transl Sci       Date:  2012-02       Impact factor: 4.689

2.  Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.

Authors:  Sharon Cresci; Jeremiah P Depta; Petra A Lenzini; Allie Y Li; David E Lanfear; Michael A Province; John A Spertus; Richard G Bach
Journal:  Circ Cardiovasc Genet       Date:  2014-04-24

3.  Routine genotyping of patients on clopidogrel: Why the resistance?

Authors:  Ganesan Karthikeyan
Journal:  Indian Heart J       Date:  2015-05-13

4.  Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.

Authors:  Jasmine A Luzum; Jason C Cheung
Journal:  Pharmacogenomics       Date:  2018-09-10       Impact factor: 2.533

5.  From hot hands to declining effects: the risks of small numbers.

Authors:  Michael S Lauer
Journal:  J Am Coll Cardiol       Date:  2012-07-03       Impact factor: 24.094

Review 6.  Towards precision medicine.

Authors:  Euan A Ashley
Journal:  Nat Rev Genet       Date:  2016-08-16       Impact factor: 53.242

7.  Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended.

Authors:  Adnan M Bhopalwala; Robert A Hong; Zia R Khan; Mona R Valentin; Ramy A Badawi
Journal:  Hawaii J Med Public Health       Date:  2015-01

Review 8.  Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Authors:  Julie A Johnson; Larisa H Cavallari
Journal:  Pharmacol Rev       Date:  2013-05-17       Impact factor: 25.468

9.  Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Authors:  Craig R Lee; Vindhya B Sriramoju; Alexandra Cervantes; Lucius A Howell; Nicholas Varunok; Shivanshu Madan; Kasey Hamrick; Melissa J Polasek; John Andrew Lee; Megan Clarke; Jonathan D Cicci; Karen E Weck; George A Stouffer
Journal:  Circ Genom Precis Med       Date:  2018-04

Review 10.  Dual antiplatelet therapy dilemmas: duration and choice of antiplatelets in acute coronary syndromes.

Authors:  Matthew Tomey; Roxana Mehran
Journal:  Curr Cardiol Rep       Date:  2013-10       Impact factor: 2.931
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.